{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:22:30Z","timestamp":1791894150820,"version":"4.3.4"},"reference-count":72,"publisher":"Portland Press Ltd.","issue":"2","license":[{"start":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T00:00:00Z","timestamp":1578009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,1,31]]},"abstract":"<jats:p>The lysosomal storage disorder Fabry disease is characterized by a deficiency of the lysosomal enzyme \u03b1-Galactosidase A. The observation that missense variants in the encoding GLA gene often lead to structural destabilization, endoplasmic reticulum retention and proteasomal degradation of the misfolded, but otherwise catalytically functional enzyme has resulted in the exploration of alternative therapeutic approaches. In this context, we have investigated proteostasis regulators (PRs) for their potential to increase cellular enzyme activity, and to reduce the disease-specific accumulation of the biomarker globotriaosylsphingosine in patient-derived cell culture. The PRs also acted synergistically with the clinically approved 1-deoxygalactonojirimycine, demonstrating the potential of combination treatment in a therapeutic application. Extensive characterization of the effective PRs revealed inhibition of the proteasome and elevation of GLA gene expression as paramount effects. Further analysis of transcriptional patterns of the PRs exposed a variety of genes involved in proteostasis as potential modulators. We propose that addressing proteostasis is an effective approach to discover new therapeutic targets for diseases involving folding and trafficking-deficient protein mutants.<\/jats:p>","DOI":"10.1042\/bcj20190513","type":"journal-article","created":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T14:43:51Z","timestamp":1578062631000},"page":"359-380","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Proteostasis regulators modulate proteasomal activity and gene expression to attenuate multiple phenotypes in Fabry disease"],"prefix":"10.1042","volume":"477","author":[{"given":"Susanne","family":"Seemann","sequence":"first","affiliation":[{"name":"Translational Neurodegeneration Section \u201cAlbrecht-Kossel\u201d, Department of Neurology, University Medical Center Rostock, University of Rostock, 18147 Rostock, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Ernst","sequence":"additional","affiliation":[{"name":"Institute for Biostatistics and Informatics in Medicine and Ageing Research, University Medical Center Rostock, 18057 Rostock, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Cimmaruta","sequence":"additional","affiliation":[{"name":"Translational Neurodegeneration Section \u201cAlbrecht-Kossel\u201d, Department of Neurology, University Medical Center Rostock, University of Rostock, 18147 Rostock, Germany"},{"name":"Institute of Biomolecular Chemistry, CNR, 80078 Pozzuoli, Italy"},{"name":"Department of Biology, University Federico II, 80126 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Struckmann","sequence":"additional","affiliation":[{"name":"Institute for Biostatistics and Informatics in Medicine and Ageing Research, University Medical Center Rostock, 18057 Rostock, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Cozma","sequence":"additional","affiliation":[{"name":"Centogene AG, Rostock, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Koczan","sequence":"additional","affiliation":[{"name":"Institute of Immunology, University Medical Center Rostock, 18057 Rostock, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Knospe","sequence":"additional","affiliation":[{"name":"Translational Neurodegeneration Section \u201cAlbrecht-Kossel\u201d, Department of Neurology, University Medical Center Rostock, University of Rostock, 18147 Rostock, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda Rebecca","family":"Haake","sequence":"additional","affiliation":[{"name":"Translational Neurodegeneration Section \u201cAlbrecht-Kossel\u201d, Department of Neurology, University Medical Center Rostock, University of Rostock, 18147 Rostock, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Citro","sequence":"additional","affiliation":[{"name":"Department of Biology, University Federico II, 80126 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja U.","family":"Br\u00e4uer","sequence":"additional","affiliation":[{"name":"Institute of Anatomy, University Medical Center Rostock, 18057 Rostock, Germany"},{"name":"Research Group Anatomy, School of Medicine and Health Sciences, Carl von Ossietzky University Oldenburg, 26129 Oldenburg, Germany"},{"name":"Research Center for Neurosensory Science, Carl von Ossietzky University Oldenburg, Oldenburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Andreotti","sequence":"additional","affiliation":[{"name":"Institute of Biomolecular Chemistry, CNR, 80078 Pozzuoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Vittoria","family":"Cubellis","sequence":"additional","affiliation":[{"name":"Institute of Biomolecular Chemistry, CNR, 80078 Pozzuoli, Italy"},{"name":"Department of Biology, University Federico II, 80126 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Fuellen","sequence":"additional","affiliation":[{"name":"Institute for Biostatistics and Informatics in Medicine and Ageing Research, University Medical Center Rostock, 18057 Rostock, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hermann","sequence":"additional","affiliation":[{"name":"Translational Neurodegeneration Section \u201cAlbrecht-Kossel\u201d, Department of Neurology, University Medical Center Rostock, University of Rostock, 18147 Rostock, Germany"},{"name":"Center for Transdisciplinary Neurosciences Rostock (CTNR), University Medical Center Rostock, University of Rostock, 18147 Rostock, Germany"},{"name":"German Center for Neurodegenerative Diseases (DZNE) Rostock\/Greifswald, 18147 Rostock, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Katrin","family":"Giese","sequence":"additional","affiliation":[{"name":"Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, U.S.A."},{"name":"Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arndt","family":"Rolfs","sequence":"additional","affiliation":[{"name":"Centogene AG, Rostock, Germany"},{"name":"University Medical Center Rostock, University of Rostock, 18057 Rostock, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8061-5798","authenticated-orcid":false,"given":"Jan","family":"Lukas","sequence":"additional","affiliation":[{"name":"Translational Neurodegeneration Section \u201cAlbrecht-Kossel\u201d, Department of Neurology, University Medical Center Rostock, University of Rostock, 18147 Rostock, Germany"},{"name":"Center for Transdisciplinary Neurosciences Rostock (CTNR), University Medical Center Rostock, University of Rostock, 18147 Rostock, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2020,1,30]]},"reference":[{"key":"2021112218044677600_BCJ-2019-0513C1","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/nrm1423","article-title":"The cell biology of lysosomal storage disorders","volume":"5","year":"2004","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2021112218044677600_BCJ-2019-0513C2","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1002\/humu.21074","article-title":"Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936\u2009+\u2009919G\u2009&gt;\u2009A (IVS4\u2009+\u2009919G\u2009&gt;\u2009A)","volume":"30","year":"2009","journal-title":"Hum. Mutat."},{"key":"2021112218044677600_BCJ-2019-0513C3","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","year":"2008","journal-title":"Proc. Natl. Acad. Sci.U.S.A."},{"key":"2021112218044677600_BCJ-2019-0513C4","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"key":"2021112218044677600_BCJ-2019-0513C5","doi-asserted-by":"publisher","first-page":"e1003632","DOI":"10.1371\/journal.pgen.1003632","article-title":"Functional characterisation of alpha-galactosidase a mutations as a basis for a new classification system in Fabry disease","volume":"9","year":"2013","journal-title":"PLoS Genet."},{"key":"2021112218044677600_BCJ-2019-0513C6","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.ymgme.2017.06.006","article-title":"Correlation of Lyso-Gb3 levels in dried blood spots and sera from patients with classic and later-onset Fabry disease","volume":"121","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"2021112218044677600_BCJ-2019-0513C7","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1161\/CIRCGENETICS.113.000249","article-title":"Gene mutations versus clinically relevant phenotypes lyso-gb3 defines fabry disease","volume":"7","year":"2014","journal-title":"Circ. Cardiovasc. Genet."},{"key":"2021112218044677600_BCJ-2019-0513C8","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1002\/emmm.200900036","article-title":"Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics","volume":"1","year":"2009","journal-title":"EMBO Mol. Med."},{"key":"2021112218044677600_BCJ-2019-0513C9","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.ymgme.2018.11.008","article-title":"Antibodies against recombinant alpha-galactosidase A in Fabry disease: subclass analysis and impact on response to treatment","volume":"126","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"2021112218044677600_BCJ-2019-0513C10","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/1750-1172-8-111","article-title":"Fabry_CEP: a tool to identify Fabry mutations responsive to pharmacological chaperones","volume":"8","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"key":"2021112218044677600_BCJ-2019-0513C11","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.bbadis.2008.03.001","article-title":"Rescue of mutant \u03b1-galactosidase A in the endoplasmic reticulum by 1-deoxygalactonojirimycin leads to trafficking to lysosomes","volume":"1782","year":"2008","journal-title":"Biochim. Biophys. Acta"},{"key":"2021112218044677600_BCJ-2019-0513C12","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nchembio.763","article-title":"Small-molecule proteostasis regulators for protein conformational diseases","volume":"8","year":"2012","journal-title":"Nat. Chem. Biol."},{"key":"2021112218044677600_BCJ-2019-0513C13","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jcf.2014.06.001","article-title":"Ibuprofen rescues mutant cystic fibrosis transmembrane conductance regulator trafficking","volume":"14","year":"2015","journal-title":"J. Cyst. Fibros."},{"key":"2021112218044677600_BCJ-2019-0513C14","doi-asserted-by":"publisher","first-page":"e68612","DOI":"10.1371\/journal.pone.0068612","article-title":"Pioglitazone improves reversal learning and exerts mixed cerebrovascular effects in a mouse model of Alzheimer's disease with combined amyloid-\u03b2 and cerebrovascular pathology","volume":"8","year":"2013","journal-title":"PLoS One"},{"key":"2021112218044677600_BCJ-2019-0513C15","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1091\/mbc.e11-08-0663","article-title":"IRE1 directs proteasomal and lysosomal degradation of misfolded rhodopsin","volume":"23","year":"2012","journal-title":"Mol. Biol. Cell"},{"key":"2021112218044677600_BCJ-2019-0513C16","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.cell.2008.06.037","article-title":"Chemical and biological approaches synergize to ameliorate protein-folding diseases","volume":"134","year":"2008","journal-title":"Cell"},{"key":"2021112218044677600_BCJ-2019-0513C17","doi-asserted-by":"publisher","first-page":"43454","DOI":"10.1074\/jbc.M111.274332","article-title":"Inhibition of endoplasmic reticulum-associated degradation rescues native folding in loss of function protein misfolding diseases","volume":"286","year":"2011","journal-title":"J. Biol. Chem."},{"key":"2021112218044677600_BCJ-2019-0513C18","doi-asserted-by":"publisher","first-page":"5620","DOI":"10.1073\/pnas.1014890108","article-title":"Histone deacetylase inhibitor treatment dramatically reduces cholesterol accumulation in Niemann-Pick type C1 mutant human fibroblasts","volume":"108","year":"2011","journal-title":"Proc. Natl. Acad. Sci.U.S.A."},{"key":"2021112218044677600_BCJ-2019-0513C19","doi-asserted-by":"publisher","first-page":"19714","DOI":"10.1074\/jbc.M114.549915","article-title":"Endoplasmic reticulum-associated degradation of Niemann-Pick C1: evidence for the role of heat shock proteins and identification of lysine residues that accept ubiquitin","volume":"289","year":"2014","journal-title":"J. Biol. Chem."},{"key":"2021112218044677600_BCJ-2019-0513C20","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/8904_2014_345","article-title":"Proteasome inhibitor Bortezomib enhances the activity of multiple mutant forms of lysosomal \u03b1-glucosidase in Pompe disease","volume":"18","year":"2015","journal-title":"JIMD Rep."},{"key":"2021112218044677600_BCJ-2019-0513C21","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.cbpa.2013.04.009","article-title":"Targeting unfolded protein response signaling pathways to ameliorate protein misfolding diseases","volume":"17","year":"2013","journal-title":"Curr. Opin. Chem. Biol."},{"key":"2021112218044677600_BCJ-2019-0513C22","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1161\/CIRCRESAHA.110.227819","article-title":"Endoplasmic reticulum stress as a therapeutic target in cardiovascular disease","volume":"107","year":"2010","journal-title":"Circ. Res."},{"key":"2021112218044677600_BCJ-2019-0513C23","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/ncb2383","article-title":"Defining human ERAD networks through an integrative mapping strategy","volume":"14","year":"2012","journal-title":"Nat. Cell Biol."},{"key":"2021112218044677600_BCJ-2019-0513C24","doi-asserted-by":"publisher","first-page":"a004507","DOI":"10.1101\/cshperspect.a004507","article-title":"Chemical and biological approaches for adapting proteostasis to ameliorate protein misfolding and aggregation diseases-progress and prognosis","volume":"3","year":"2011","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"2021112218044677600_BCJ-2019-0513C25","doi-asserted-by":"publisher","first-page":"e10365","DOI":"10.7554\/eLife.10365","article-title":"Unravelling druggable signalling networks that control F508del-CFTR proteostasis","volume":"4","year":"2015","journal-title":"eLife"},{"key":"2021112218044677600_BCJ-2019-0513C26","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/j.celrep.2013.03.024","article-title":"Stress-independent activation of XBP1s and\/or atf6 reveals three functionally diverse ER proteostasis environments","volume":"3","year":"2013","journal-title":"Cell Rep."},{"key":"2021112218044677600_BCJ-2019-0513C27","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.tcb.2017.05.006","article-title":"Regulating secretory proteostasis through the unfolded protein response: from function to therapy","volume":"27","year":"2017","journal-title":"Trends Cell Biol."},{"key":"2021112218044677600_BCJ-2019-0513C28","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1021\/cb100321m","article-title":"Ca2+ homeostasis modulation enhances the amenability of L444P glucosylcerebrosidase to proteostasis regulation in patient-derived fibroblasts","volume":"6","year":"2011","journal-title":"ACS Chem. Biol."},{"key":"2021112218044677600_BCJ-2019-0513C29","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1371\/journal.pbio.0060026","article-title":"Partial restoration of mutant enzyme homeostasis in three distinct lysosomal storage disease cell lines by altering calcium homeostasis","volume":"6","year":"2008","journal-title":"PLoS Biol."},{"key":"2021112218044677600_BCJ-2019-0513C30","doi-asserted-by":"publisher","first-page":"355ra118","DOI":"10.1126\/scitranslmed.aad9823","article-title":"Heat shock protein-based therapy as a potential candidate for treating the sphingolipidoses","volume":"8","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"2021112218044677600_BCJ-2019-0513C31","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1093\/hmg\/ddm324","article-title":"ER and oxidative stresses are common mediators of apoptosis in both neurodegenerative and non-neurodegenerative lysosomal storage disorders and are alleviated by chemical chaperones","volume":"17","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"2021112218044677600_BCJ-2019-0513C32","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1039\/C6MT00148C","article-title":"A systems biology approach reveals new endoplasmic reticulum-associated targets for the correction of the ATP7B mutant causing Wilson disease","volume":"8","year":"2016","journal-title":"Metallomics"},{"key":"2021112218044677600_BCJ-2019-0513C33","doi-asserted-by":"publisher","first-page":"e15550","DOI":"10.7554\/eLife.15550","article-title":"Small molecule proteostasis regulators that reprogram the ER to reduce extracellular protein aggregation","volume":"5","year":"2016","journal-title":"eLife"},{"key":"2021112218044677600_BCJ-2019-0513C34","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1042\/BJ20070479","article-title":"Mutant alpha-galactosidase A enzymes identified in Fabry disease patients with residual enzyme activity: biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycin","volume":"406","year":"2007","journal-title":"Biochem. J."},{"key":"2021112218044677600_BCJ-2019-0513C35","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1038\/mt.2014.224","article-title":"Enzyme enhancers for the treatment of Fabry and Pompe disease","volume":"23","year":"2015","journal-title":"Mol. Ther."},{"key":"2021112218044677600_BCJ-2019-0513C36","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.gene.2014.08.004","article-title":"An intronic haplotype in \u03b1 galactosidase A is associated with reduced mRNA expression in males with cryptogenic stroke","volume":"549","year":"2014","journal-title":"Gene"},{"key":"2021112218044677600_BCJ-2019-0513C37","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1007\/s10545-009-1077-0","article-title":"The pharmacological chaperone 1-deoxygalactonojirimycin increases alpha-galactosidase A levels in Fabry patient cell lines","volume":"32","year":"2009","journal-title":"J. Inherit. Metab. Dis."},{"key":"2021112218044677600_BCJ-2019-0513C38","doi-asserted-by":"publisher","first-page":"E2010","DOI":"10.3390\/ijms17122010","article-title":"The large phenotypic spectrum of fabry disease requires graduated diagnosis and personalized therapy: a meta-analysis can help to differentiate missense mutations","volume":"17","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"2021112218044677600_BCJ-2019-0513C39","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/humu.22910","article-title":"Functional and clinical consequences of novel \u03b1-galactosidase a mutations in Fabry disease","volume":"37","year":"2016","journal-title":"Hum. Mutat."},{"key":"2021112218044677600_BCJ-2019-0513C40","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1139\/y59-099","article-title":"A rapid method of total lipid extraction and purification","volume":"37","year":"1959","journal-title":"Can. J. Biochem. Physiol."},{"key":"2021112218044677600_BCJ-2019-0513C41","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/978-1-59745-542-8_55","article-title":"TLC blot (far-eastern blot) and its applications","volume":"536","year":"2009","journal-title":"Methods Mol. Biol."},{"key":"2021112218044677600_BCJ-2019-0513C42","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/978-1-4939-7493-1_17","article-title":"Methods for high-throughput drug combination screening and synergy scoring","volume":"1711","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"2021112218044677600_BCJ-2019-0513C43","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1111\/j.1744-7348.1939.tb06990.x","article-title":"The toxicity of poisons applied jointly","volume":"26","year":"1939","journal-title":"Ann. Appl. Biol."},{"key":"2021112218044677600_BCJ-2019-0513C44","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1083\/jcb.201210077","article-title":"Development of proteasome inhibitors as research tools and cancer drugs","volume":"199","year":"2012","journal-title":"J. Cell Biol."},{"key":"2021112218044677600_BCJ-2019-0513C45","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1093\/nar\/29.9.e45","article-title":"A new mathematical model for relative quantification in real-time RT\u2013PCR","volume":"29","year":"2001","journal-title":"Nucleic Acids Res."},{"key":"2021112218044677600_BCJ-2019-0513C46","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1093\/biostatistics\/4.2.249","article-title":"Exploration, normalization, and summaries of high density oligonucleotide array probe level data","volume":"4","year":"2003","journal-title":"Biostatistics"},{"key":"2021112218044677600_BCJ-2019-0513C47","unstructured":"Carlson, M. (2015) org.Hs.eg.db: Genome wide annotation for Human. R package version 3.2.3"},{"key":"2021112218044677600_BCJ-2019-0513C48","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1158\/1535-7163.MCT-05-0147","article-title":"Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells","volume":"5","year":"2006","journal-title":"Mol Cancer Ther."},{"key":"2021112218044677600_BCJ-2019-0513C49","doi-asserted-by":"publisher","first-page":"D488","DOI":"10.1093\/nar\/gkv1024","article-title":"Wikipathways: capturing the full diversity of pathway knowledge","volume":"44","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"2021112218044677600_BCJ-2019-0513C50","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s40265-016-0607-y","article-title":"Migalastat: first global approval","volume":"76","year":"2016","journal-title":"Drugs"},{"key":"2021112218044677600_BCJ-2019-0513C51","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s12863-015-0267-z","article-title":"Increased glycolipid storage produced by the inheritance of a complex intronic haplotype in the \u03b1-galactosidase A (GLA) gene","volume":"16","year":"2015","journal-title":"BMC Genet."},{"key":"2021112218044677600_BCJ-2019-0513C52","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1093\/ndt\/gfq306","article-title":"Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy","volume":"26","year":"2011","journal-title":"Nephrol. Dial. Transplant."},{"key":"2021112218044677600_BCJ-2019-0513C53","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s00280-010-1283-3","article-title":"Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma","volume":"67","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"key":"2021112218044677600_BCJ-2019-0513C54","doi-asserted-by":"publisher","first-page":"4450","DOI":"10.1111\/febs.12954","article-title":"The proteasome inhibitor bortezomib reduced cholesterol accumulation in fibroblasts from Niemann-Pick type C patients carrying missense mutations","volume":"281","year":"2014","journal-title":"FEBS J."},{"key":"2021112218044677600_BCJ-2019-0513C55","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/gim.2016.122","article-title":"The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat","volume":"19","year":"2017","journal-title":"Genet Med."},{"key":"2021112218044677600_BCJ-2019-0513C56","unstructured":"Amicus Therapeutics U.S., Inc. GALAFOLD\u2122 Prescribing Information; Revised: 08\/2018;https:\/\/www.galafold.com\/app\/uploads\/2018\/08\/galafold.pdf"},{"key":"2021112218044677600_BCJ-2019-0513C57","doi-asserted-by":"publisher","first-page":"448","DOI":"10.3389\/fphar.2017.00448","article-title":"Pharmaceutical chaperones and proteostasis regulators in the therapy of lysosomal storage disorders: current perspective and future promises","volume":"8","year":"2017","journal-title":"Front. Pharmacol."},{"key":"2021112218044677600_BCJ-2019-0513C58","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","article-title":"Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study","volume":"54","year":"2017","journal-title":"J. Med. Genet."},{"key":"2021112218044677600_BCJ-2019-0513C59","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1002\/jcph.906","article-title":"Population pharmacokinetic analysis of Bortezomib in pediatric leukemia patients: model-based support for body surface area-based dosing over the 2- to 16-year age range","volume":"57","year":"2017","journal-title":"J. Clin. Pharmacol."},{"key":"2021112218044677600_BCJ-2019-0513C60","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1002\/1873-3468.12104","article-title":"Lysosomal glycosphingolipid catabolism by acid ceramidase: formation of glycosphingoid bases during deficiency of glycosidases","volume":"590","year":"2016","journal-title":"FEBS Lett."},{"key":"2021112218044677600_BCJ-2019-0513C61","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1136\/jmedgenet-2019-106005","article-title":"Mutation-specific Fabry disease patient-derived cell model to evaluate the amenability to chaperone therapy","volume":"56","year":"2019","journal-title":"J. Med. Genet."},{"key":"2021112218044677600_BCJ-2019-0513C62","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.bbrc.2015.11.050","article-title":"Lyso-globotriaosylceramide downregulates KCa3.1 channel expression to inhibit collagen synthesis in fibroblasts","volume":"468","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2021112218044677600_BCJ-2019-0513C63","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/4801","article-title":"Accelerated transport and maturation of lysosomal \u03b1-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor","volume":"5","year":"1999","journal-title":"Nat. Med."},{"key":"2021112218044677600_BCJ-2019-0513C64","doi-asserted-by":"publisher","first-page":"441","DOI":"10.14348\/molcells.2017.0115","article-title":"Crosstalk and interplay between the ubiquitin-proteasome system and autophagy","volume":"40","year":"2017","journal-title":"Mol. Cells"},{"key":"2021112218044677600_BCJ-2019-0513C65","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/ncb3177","article-title":"Amino-terminal arginylation targets endoplasmic reticulum chaperone BiP for autophagy through p62 binding","volume":"17","year":"2015","journal-title":"Nat. Cell Biol."},{"key":"2021112218044677600_BCJ-2019-0513C66","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1194\/jlr.R046896","article-title":"Lysosomal exocytosis and lipid storage disorders","volume":"55","year":"2014","journal-title":"J. Lipid Res."},{"key":"2021112218044677600_BCJ-2019-0513C67","doi-asserted-by":"publisher","first-page":"E2089","DOI":"10.3390\/ijms17122089","article-title":"Using CRISPR\/Cas9-mediated GLA gene knockout as an in vitro drug screening model for Fabry disease","volume":"17","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"2021112218044677600_BCJ-2019-0513C68","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.bbagrm.2010.08.001","article-title":"The proteasome and its regulatory roles in gene expression","volume":"1809","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"2021112218044677600_BCJ-2019-0513C69","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s10555-010-9255-y","article-title":"Feedback regulation of proteasome gene expression and its implications in cancer therapy","volume":"29","year":"2010","journal-title":"Cancer Metastasis Rev."},{"key":"2021112218044677600_BCJ-2019-0513C70","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1146\/annurev-pharmtox-011112-140320","article-title":"Role of nrf2 in oxidative stress and toxicity","volume":"53","year":"2013","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"2021112218044677600_BCJ-2019-0513C71","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/S1534-5807(03)00032-7","article-title":"IRE1: a role in UPREgulation of ER degradation","volume":"4","year":"2003","journal-title":"Dev. Cell"},{"key":"2021112218044677600_BCJ-2019-0513C72","doi-asserted-by":"publisher","first-page":"bat024","DOI":"10.1093\/database\/bat024","article-title":"hLGDB: a database of human lysosomal genes and their regulation","volume":"2013","year":"2013","journal-title":"Database (Oxford)"}],"container-title":["Biochemical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/biochemj\/article-pdf\/477\/2\/359\/866702\/bcj-2019-0513.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/biochemj\/article-pdf\/477\/2\/359\/866702\/bcj-2019-0513.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T02:27:51Z","timestamp":1637634471000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/biochemj\/article\/477\/2\/359\/221764\/Proteostasis-regulators-modulate-proteasomal"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,30]]},"references-count":72,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,1,31]]}},"URL":"https:\/\/doi.org\/10.1042\/bcj20190513","relation":{},"ISSN":["0264-6021","1470-8728"],"issn-type":[{"value":"0264-6021","type":"print"},{"value":"1470-8728","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,30]]}}}